Table 2.

Percentage of Patients (95% CI) With Pain Relief and Pain Freedom in the Ketorolac vs Sumatripan vs Placebo Nasal Migraine Study

	Placebo % (95% CI)	Ketorolac NS % (95% CI)	P-Value* vs Placebo	Sumatriptan NS % (95% CI)	P-Value vs Placebo	P-Value vs Ketorolac
2-hour pain relief	38.8 (24.6–52.9)	72.5 (59.9–85.2)	<.001	69.4 (56.0–82.8)	.001	.724
2–24-hour sustained pain relief	20.4 (8.7–32.1)	49.0 (34.8–63.2)	<.001	40.8 (26.5–55.1)	.011	.070
2–48-hour sustained pain relief	20.4 (8.7–32.1)	49.0 (34.8–63.2)	<.001	30.6 (17.2–43.9)	.200	.313
2-hour pain freedom	18.4 (7.1–29.6)	43.1 (29.1–57.2)	.004	36.7 (22.7–50.7)	.046	.513
2–24-hour sustained pain freedom	12.2 (2.7–21.7)	35.3 (21.7–48.9)	.003	22.4 (10.3–34.5)	.184	.381
2–48-hour sustained pain freedom	12.2 (2.7–21.7)	33.3 (19.9–46.7)	.006	18.4 (7.1–29.6)	.060	.915

^*P-values computed using a mixed longitudinal model.